Clinical Trials Logo

Pelvic Neoplasms clinical trials

View clinical trials related to Pelvic Neoplasms.

Filter by:

NCT ID: NCT00191646 Completed - Ovarian Neoplasms Clinical Trials

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Start date: October 2002
Phase: Phase 3
Study type: Interventional

This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.

NCT ID: NCT00191607 Completed - Ovarian Neoplasms Clinical Trials

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Start date: July 2002
Phase: Phase 3
Study type: Interventional

This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment. The purpose of this trial is to compare progression free survival between gemcitabine and liposomal doxorubicin. Progression free survival (PFS) is defined as the period from study entry until disease progression

NCT ID: NCT00186953 Completed - Pelvic Neoplasms Clinical Trials

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

Start date: June 2002
Phase: Phase 1
Study type: Interventional

St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's Research Hospital researchers want to learn the best and safest dose of this ultrasound "dye."